Abstract
The level of bioactive transforming growth factor-β (TGF-β) was measured in serum from patients with chronic fatigue syndrome (CFS), healthy control subjects, and patients with major depression, systemic lupus erythematosis (SLE), and multiple sclerosis (MS) of both the relapsing/remitting (R/R) and the chronic progressive (CP) types. Patients with CFS had significantly higher levels of bioactive TGF-β levels compared to the healthy control, major depression, SLE, R/R MS, and CP MS groups (P < 0.01). Additionally, no significant differences were found between the healthy control subjects and any of the disease comparison groups. The current finding that TGF-β is significantly elevated among patients with CFS supports the findings of two previous studies examining smaller numbers of CFS patients. In conclusion, TGF-β levels were significantly higher in CFS patients compared to patients with various diseases known to be associated with immunologic abnormalities and/or pathologic fatigue. These findings raise interesting questions about the possible role of TGF-β in the pathogenesis of CFS.
Similar content being viewed by others
REFERENCES
Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JF, DuBois RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegans LS, Purtilo DT, Brown N, Schooley RT, Brus I: Chronic fatigue syndrome: A working case definition. Ann Intern Med 108:387–389, 1988
Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121:953–959, 1994
Lloyd AR, Wakefield D, Hickie I: Immunity and the pathophysiology of chronic fatigue syndrome. In Chronic Fatigue Syndrome (Ciba Foundation Symposium 173), GR Bock, J Whelan (eds). New York, John Wiley & Sons, 1993, pp 176–192
Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA: Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 18 (Suppl 1):S136-S141, 1994
McDonald EM, Mann AH, Thomas HC: Interferons as mediators of psychiatric morbidity: An investigation in a trial of recombinant α-interferon in hepatitis-B carriers. Lancet 2:1175–1178, 1987
Krueger JM, Majde JA: Sleep as a host defense: Its regulation by microbial products and cytokines. Clin Immunol Immunopathol 57:188–199, 1990
Linde A, Andersson B, Svenson SB, Ahrne H, Carlsson M, Forsberg P, Hugo H, Karstorp A, Lenkei R, Lindwall A, Loftenius A, Sall C, Andersson J: Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 165:994–1000, 1992
Cheney PR, Dorman SE: Interleukin-2 and the chronic fatigue syndrome. Ann Intern Med 110:321, 1989
Chao CC, Gallagher M, Phair J, Peterson PK: Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis 162:1412–1413, 1990
Ho-Yen DO, Carrington D, Armstrong AA: Myalgic encephalomyelitis and alpha-interferon. Lancet 1:125, 1988
Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA: Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: Interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 18 (Suppl 1):S147-S153, 1994
Straus SE, Dale JK, Peter JB, Dinarello CA: Circulating lymphokine levels in chronic fatigue syndrome. J Infect Dis 160:1085–1086, 1989
Lloyd A, Gandevia S, Brockman A, Hales J, Wakefield D: Cytokine production and fatigue in patients with chronic fatigue syndrome and healthy control subjects in response to exercise. Clin Infect Dis 18 (Suppl 1):S142-S146, 1994
Chao CC, Janoff EN, Hu S, Thomas K, Gallagher M, Tsang M, et al.: Altered cytokine release in peripheral blood mononuclear cell cultures from patients with chronic fatigue syndrome. Cytokine 3:292–398, 1991
Peterson PK, Sirr SA, Grammith FC, Schenk C, Pheley AM, Hu S, Chao CC: Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients. Clin Diag Lab Immunol 1:222–226, 1994
Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-β: Biological function and chemical structure. Science 233:532–534, 1986
Sporn MB, Roberts AB: Introduction: What is TGF-β? In Clinical Applications of TGF-β (Ciba Foundation Symposium 157), GR Bock, J Marsh (eds). New York, John Wiley & Sons, 1991, pp 1–5
Massague J: The transforming growth factor-β family. Annu Rev Cell Biol 6:597–641, 1990
Roberts AB, Sporn MB: The transforming growth factor-βs. In Handbook of Experimental Pharmacology, Peptide Growth Factors and Their Receptors, Vol 95, Part 1, MB Sporn, AB Roberts (eds). Heidelberg, Springer-Verlag, 1990, pp 419–472
Miyazono K, Yuki K, Takaku F, Wernstedt C, Kanzaki T, Olofsson A, Hellman U, Heldin CH: Latent forms of TGF-β: Structure and biology. Ann NY Acad Sci 593:51–58, 1990
Ruscetti F, Varesio L, Ochoa A, Ortaldo J: Pleiotropic effects of transforming growth factor-β on cells of the immune system. Ann NY Acad Sci 685:488–500, 1993
Fontana A, Constam DB, Frei K, Malipiero U, Pfister HW. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 99:1–7, 1992
Lucas C, Wallick S, Fendly BM, Figarit I, Palladino MA: TGF-β: A possible autocrine immune regulator. In Clinical Applications of TGF-β (Ciba Foundation Symposium 157), GR Bock, J Marsh (eds). New York, John Wiley & Sons, 1991, pp 98–114
Wahl SM, Costa GL, Mizel DE, Allen JB, Skaleric U, Mangan DF: Role of transforming growth factor beta in the pathophysiology of chronic inflammation. J Periodontol 64:450–455, 1993
Smith EA, LeRoy EC: A possible role for transforming growth factor-β in systemic sclerosis. J Invest Dermatol 95:125S-127S, 1990
Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T: Co-localization of transforming growth factor β2 with α1(1) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86:917–922, 1990
Kanai H, Mitsuhashi H, Ono K, Yano S, Naruse T: Increased excretion of urinary transforming growth factor beta in patients with focal glomerular sclerosis. Nephron 66:391–395, 1994
Deguchi Y, Kishimoto S: Spontaneous activation of Transforming growth factor-β gene transcription in broncho-alveolar mononuclear cells of individuals with systemic autoimmune diseases with lung involvement. Lupus 1:27–30, 1991
Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and sjogren's syndrome-like lymphoproliferation in TGF-β knockout mice. J Immunol 155:3205–3212, 1995
Horwitz DA, Wang H, Gray JD: Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosis: Increased interleukin-2 but not interleukin-4 mRNA. Lupus 3:423–428, 1994
Rieckmann P, Albrecht BA, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S: Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37:82–88, 1995
Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H: Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann Neurol 36:379–386, 1994
Link J, He B, Navikas V, Palasik W, Fredrikson S, Soderstrom M, Link H: Transforming growth factor-β1 suppresses autoantigen-induced expression of proinflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. J Neuroimmunol 58:21–35, 1995
Beck J, Rondot P, Jullien P, Wietzerbin J, Lawrence DA: TGF-β-like activity produced during regression of exacerbations in multiple sclerosis. Acta Neurol Scand 84:452–455, 1991
Hafler DA, Chofflon M, Kurt-Jones E, Weiner HL: Interleukin-1 corrects the defective autologous mixed lymphocyte response in multiple sclerosis. Clin Immunol Immunopathol 58:115–125, 1991
Kekow J, Wachsman W, McCutchan JA, Cronin M, Carson DA, Lotz M: Transforming growth factor β and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 87:8321–8325, 1990
Landay AL, Jessop C, Lennette ET, Levy JA: Chronic fatigue syndrome: Clinical condition associated with immune activation. Lancet 338:707–712, 1991
Straus SE, Fritz S, Dale JK, Gould B, Strober W: Lymphocyte phenotype and function in the chronic fatigue syndrome. J Clin Immunol 13:30–40, 1993
Constam DB, Phillip J, Malipiero UV, ten Dijke P, Schachner M, Fontana A: Differential expression of transforming growth factor-β1, β2, and β3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404–1410, 1992
da Cunha A, Jefferson JA, Jackson RW, Vitkovic L: Glial cell-specific mechanisms of TGF-β1 induction by IL-1 in cerebral cortex. J Neuroimmunol 42:71–86, 1993
Wahl SM, Allen JB, McCartney-Francis N, Morganti-Kossmann MC, Kossmann T, Ellingsworth L, Mai UEH, Mergenhagen SE, Orenstein JM: Macrophage-and astrocyte-derived transforming growth factor β as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med 173: 981–991, 1991
Chao CC, Hu S, Frey WH, II, Ala T, Tourtellotte WW, Peterson PK: Transforming growth factor-β in Alzheimer's disease. Clin Diagn Lab Immunol 1:109–110, 1994
Chao CC, Hu S, Kravitz FH, Anderson WR, Tsang M, Peterson PK: Transforming growth factor-β protects human neurons against β-amyloid-induced injury. Mol Chem Neuropathol 23:159–178, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bennett, A.L., Chao, C.C., Hu, S. et al. Elevation of Bioactive Transforming Growth Factor-β in Serum from Patients with Chronic Fatigue Syndrome. J Clin Immunol 17, 160–166 (1997). https://doi.org/10.1023/A:1027330616073
Issue Date:
DOI: https://doi.org/10.1023/A:1027330616073